$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

$fold Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000110465914034647 Filed on May 05, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$475.0K	$456.0K	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.750M	$5.180M	$4.820M
YoY Change	-1.66%	7.47%	17.56%
% of Gross Profit
Research & Development	$9.978M	$9.992M	$11.99M
YoY Change	-6.97%	-16.66%	-14.39%
% of Gross Profit
Depreciation & Amortization	$400.0K	$410.0K	$440.0K
YoY Change	-11.11%	-6.82%	4.76%
% of Gross Profit
Operating Expenses	$14.74M	$16.08M	$17.25M
YoY Change	-7.9%	-6.81%	-6.85%
Operating Profit	-$14.27M	-$15.62M	-$17.25M
YoY Change	-10.87%	-9.45%	60.55%
Interest Expense	$374.0K	$355.0K	$10.00K
YoY Change	4055.56%	3450.0%	-76.74%
% of Operating Profit
Other Income/Expense, Net	-$10.00K	-$9.000K	$0.00
YoY Change
Pretax Income	-$14.61M	-$15.94M	-$17.46M
YoY Change	-4.81%	-8.68%	32.89%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$14.61M	-$15.94M	-$17.46M
YoY Change	-4.79%	-8.68%	32.89%
Net Earnings / Revenue	-3076.63%	-3496.27%
Basic Earnings Per Share
Diluted Earnings Per Share	-$217.4K	-$247.7K	-$351.9K
COMMON SHARES
Basic Shares Outstanding	64.34M shares	62.26M shares	49.63M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$78.00M	$71.70M	$84.80M
YoY Change	5.12%	-15.45%	-21.63%
Cash & Equivalents	$41.90M	$27.53M	$26.74M
Short-Term Investments	$36.10M	$44.10M	$58.00M
Other Short-Term Assets	$951.0K	$1.758M	$1.753M
YoY Change	-51.92%	0.29%	-37.15%
Inventory
Prepaid Expenses
Receivables	$500.0K	$0.00	$1.300M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$79.42M	$73.45M	$87.81M
YoY Change	2.91%	-16.36%	-23.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.444M	$3.748M	$4.962M
YoY Change	-26.96%	-24.47%	-2.19%
Goodwill	$11.61M	$11.61M
YoY Change
Intangibles	$23.00M	$23.00M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$515.0K	$546.0K	$442.0K
YoY Change	16.52%	23.53%	0.0%
Total Long-Term Assets	$38.57M	$38.91M	$5.404M
YoY Change	647.95%	619.97%	-2.01%
TOTAL ASSETS
Total Short-Term Assets	$79.42M	$73.45M	$87.81M
Total Long-Term Assets	$38.57M	$38.91M	$5.404M
Total Assets	$118.0M	$112.4M	$93.22M
YoY Change	43.31%	20.53%	-22.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.900M	$9.200M	$6.400M
YoY Change	10.0%	43.75%	-23.81%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.300M	$200.0K	$400.0K
YoY Change	225.0%	-50.0%	-63.64%
Total Short-Term Liabilities	$11.17M	$9.366M	$7.995M
YoY Change	12.08%	17.15%	-55.0%
LONG-TERM LIABILITIES
Long-Term Debt	$13.10M	$14.20M	$200.0K
YoY Change	13000.0%	7000.0%	-66.67%
Other Long-Term Liabilities	$748.0K	$723.0K	$31.70M
YoY Change	-97.71%	-97.72%	46.08%
Total Long-Term Liabilities	$748.0K	$723.0K	$31.90M
YoY Change	-97.72%	-97.73%	43.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.17M	$9.366M	$7.995M
Total Long-Term Liabilities	$748.0K	$723.0K	$31.90M
Total Liabilities	$11.92M	$10.09M	$39.90M
YoY Change	-72.15%	-74.71%	-0.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$409.1M	-$394.5M	-$336.3M
YoY Change	16.32%	17.28%	18.75%
Common Stock	$445.4M	$425.5M	$389.7M
YoY Change	13.84%	9.21%	7.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$36.31M	$31.08M	$53.34M
YoY Change
Total Liabilities & Shareholders Equity	$118.0M	$112.4M	$93.22M
YoY Change	43.31%	20.53%	-22.84%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$14.61M	-$15.94M	-$17.46M
YoY Change	-4.79%	-8.68%	32.89%
Depreciation, Depletion And Amortization	$400.0K	$410.0K	$440.0K
YoY Change	-11.11%	-6.82%	4.76%
Cash From Operating Activities	-$11.82M	-$10.22M	-$13.90M
YoY Change	15.2%	-26.47%	72.89%
INVESTING ACTIVITIES
Capital Expenditures	-$90.00K	$40.00K	$372.0K
YoY Change	-57.14%	-89.25%	-87.93%
Acquisitions
YoY Change
Other Investing Activities	$8.030M	-$5.760M	$7.140M
YoY Change	10.0%	-180.67%	-113.32%
Cash From Investing Activities	$7.930M	-$5.800M	$6.770M
YoY Change	11.69%	-185.67%	-111.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	18.26M	-90.00K	-100.0K
YoY Change	-18360.0%	-10.0%	-100.16%
NET CHANGE
Cash From Operating Activities	-11.82M	-10.22M	-13.90M
Cash From Investing Activities	7.930M	-5.800M	6.770M
Cash From Financing Activities	18.26M	-90.00K	-100.0K
Net Change In Cash	14.37M	-16.11M	-7.230M
YoY Change	-540.8%	122.82%	528.7%
FREE CASH FLOW
Cash From Operating Activities	-$11.82M	-$10.22M	-$13.90M
Capital Expenditures	-$90.00K	$40.00K	$372.0K
Free Cash Flow	-$11.73M	-$10.26M	-$14.27M
YoY Change	16.72%	-28.11%	28.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7500000	shares
CY2013Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1600000	shares
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27533000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	43640000	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-394465000	USD
CY2010Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4950000	shares
CY2010Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1900000	shares
CY2010Q1	fold	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	17100000	USD
CY2012Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	11500000	shares
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	62000000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1260000	USD
CY2013Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	15000000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43640000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	27533000	USD
CY2014Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	71652000	USD
CY2013Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	81999000	USD
CY2014Q1	fold	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	10000	USD
CY2013Q4	fold	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	USD
CY2013Q4	fold	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6000	USD
CY2014Q1	fold	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000	USD
CY2014Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	44121000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	38360000	USD
CY2014Q1	fold	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	71654000	USD
CY2013Q4	fold	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	82000000	USD
CY2013	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2014Q1	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2014Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	24200000	USD
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	23600000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	14000	USD
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	15000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1000	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
CY2010Q1	fold	Proceeds From Issuance Of Common Stock Gross ProceedsFromIssuanceOfCommonStockGross	18500000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-85000	USD
CY2010Q1	fold	Stock Issued During Period Shares Collaboration Agreement StockIssuedDuringPeriodSharesCollaborationAgreement	4900000	shares
CY2010Q1	fold	Number Of Shares Of Common Stock Sold In One Unit NumberOfSharesOfCommonStockSoldInOneUnit	1	shares
CY2010Q1	fold	Number Of Warrants Sold In One Unit NumberOfWarrantsSoldInOneUnit	1	shares
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1574000	USD
CY2010Q1	us-gaap	Share Price SharePrice	3.74
CY2012Q1	us-gaap	Share Price SharePrice	5.70
CY2012Q1	fold	Proceeds From Issuance Of Common Stock Gross ProceedsFromIssuanceOfCommonStockGross	65600000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	11613000	USD
CY2014Q1	us-gaap	Goodwill Goodwill	11613000	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2014Q1	fold	Common Stock Voting Rights For Each Share Held CommonStockVotingRightsForEachShareHeld	1	item
CY2014Q1	fold	Number Of Inputs Used To Determine Value Of Warrants NumberOfInputsUsedToDetermineValueOfWarrants	6	item
CY2010Q1	fold	Portion Of Share Purchased In One Unit PortionOfSharePurchasedInOneUnit	0.375	shares
CY2010Q1	fold	Warrant Term WarrantTerm	P4Y
CY2010Q1	fold	Exercise Period Of Warrant On Or After Issued ExercisePeriodOfWarrantOnOrAfterIssued	P6M
CY2014Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2014Q1	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2010Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	4.43
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	48000	USD
CY2013Q4	us-gaap	Restructuring Reserve RestructuringReserve	1842000	USD
CY2014Q1	us-gaap	Restructuring Reserve RestructuringReserve	1031000	USD
CY2014Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	-803000	USD
CY2014Q1	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	-8000	USD
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	AMICUS THERAPEUTICS INC
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001178879
CY2014Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	44121000	USD
CY2014Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	38000	USD
CY2014Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1758000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3748000	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	546000	USD
CY2014Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9167000	USD
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	64340526	shares
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	38360000	USD
CY2013Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	759000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5519000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	88278000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4120000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	552000	USD
CY2013Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	299000	USD
CY2013Q4	us-gaap	Assets Assets	127563000	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10162000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Gross Noncurrent DeferredTaxLiabilitiesGrossNoncurrent	9186000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	714000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	679000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	423593000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-378522000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	45751000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	127563000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	73450000	USD
CY2014Q1	us-gaap	Assets Assets	112357000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	9366000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	112357000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	31084000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10385000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10461000	USD
CY2013Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	36677000	USD
CY2013Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	14174000	USD
CY2013Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	10600000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9973000	USD
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61975416	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61975416	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	64340259	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	64340259	shares
CY2013Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11989000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4823000	USD
CY2013Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	439000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	17251000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17251000	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	456000	USD
CY2014Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	9992000	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5176000	USD
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	412000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	16077000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15621000	USD
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	42000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	355000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-15943000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-15943000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15943000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	64353952	shares
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49621188	shares
	fold	Research Revenue ResearchRevenue	58312000	USD
	fold	Collaboration Revenue CollaborationRevenue	64382000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	122694000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	367829000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	156682000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3502000	USD
	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	1030000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13899000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	418000	USD
	us-gaap	Operating Expenses OperatingExpenses	543865000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-421171000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	14605000	USD
	us-gaap	Interest Expense InterestExpense	2823000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2461000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	243000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-394465000	USD
	fold	Deemed Dividend DeemedDividend	19424000	USD
	us-gaap	Temporary Equity Accretion Of Dividends TemporaryEquityAccretionOfDividends	-802000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-414691000	USD
CY2013Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	65000	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	10000	USD
CY2013Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	262000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-17458000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-17458000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17458000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	1000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	2000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17457000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-394463000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15942000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	584000	USD
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	522000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	49366000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	853000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-388000	USD
	fold	Stock Based License Payments StockBasedLicensePayments	1220000	USD
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	-135000	USD
CY2013Q4	us-gaap	Restructuring Charges RestructuringCharges	1900000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	38000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1758000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	466000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5723000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	36677000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-284366000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	850244000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	894481000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18948000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-63185000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	143022000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	208441000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5000000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	5587000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	4554000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	110000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3356000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	264000	USD
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	5611000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	19641000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	375084000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	27533000	USD
	us-gaap	Interest Paid InterestPaid	2355000	USD
	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	386000	USD
	fold	Conversion Of Notes Payable To Preferred Stock ConversionOfNotesPayableToPreferredStock	5000000	USD
CY2013Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	26998000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	148951000	USD
	fold	Accretion Of Redeemable Convertible Preferred Stock AccretionOfRedeemableConvertiblePreferredStock	802000	USD
	fold	Beneficial Conversion Feature Related To Issuance Of Series C Redeemable Convertible Preferred Stock BeneficialConversionFeatureRelatedToIssuanceOfSeriesCRedeemableConvertiblePreferredStock	19424000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1574000	USD
CY2013Q1	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-1917000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-517000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2418000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1267000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13900000	USD
CY2013Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	34135000	USD
CY2013Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1200000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	38359000	USD
CY2014Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	44119000	USD
CY2014Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	199000	USD
CY2014Q1	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	36677000	USD
CY2014Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	14216000	USD
CY2014Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	11105000	USD
CY2014Q1	us-gaap	Deferred Tax Liabilities Gross Noncurrent DeferredTaxLiabilitiesGrossNoncurrent	9186000	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	723000	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	703000	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	424844000	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	13000	USD
CY2013Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	17839000	USD
CY2013Q4	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	11600000	USD
CY2013Q4	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	23000000	USD
CY2014Q1	fold	Research Revenue ResearchRevenue	456000	USD
CY2014Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	505000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	505000	USD
CY2014Q1	us-gaap	Restructuring Charges RestructuringCharges	-8000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	0	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	372000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	6765000	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-100000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-7235000	USD
CY2013Q1	us-gaap	Interest Paid InterestPaid	7000	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	208000	USD
CY2014Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	59000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1260000	USD
CY2014Q1	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-721000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3761000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-987000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10220000	USD
CY2014Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	11465000	USD
CY2014Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	17227000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	40000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5802000	USD
CY2014Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	100000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-16107000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33971000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26736000	USD

Files In Submission

Name	View Source	Status
0001104659-14-034647-index-headers.html	Edgar Link	pending
0001104659-14-034647-index.html	Edgar Link	pending
0001104659-14-034647.txt	Edgar Link	pending
0001104659-14-034647-xbrl.zip	Edgar Link	pending
a14-9714_110q.htm	Edgar Link	pending
a14-9714_1ex10d6.htm	Edgar Link	pending
a14-9714_1ex10d7.htm	Edgar Link	pending
a14-9714_1ex10d8.htm	Edgar Link	pending
a14-9714_1ex31d1.htm	Edgar Link	pending
a14-9714_1ex31d2.htm	Edgar Link	pending
a14-9714_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fold-20140331.xml	Edgar Link	completed
fold-20140331.xsd	Edgar Link	pending
fold-20140331_cal.xml	Edgar Link	unprocessable
fold-20140331_def.xml	Edgar Link	unprocessable
fold-20140331_lab.xml	Edgar Link	unprocessable
fold-20140331_pre.xml	Edgar Link	unprocessable
g97141lei001.jpg	Edgar Link	pending
g97141lgi001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

2014 Q2 Form 10-Q Financial Statement

#000110465914034647 Filed on May 05, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD AMICUS THERAPEUTICS, INC. Stock $fold

2014 Q2 Form 10-Q Financial Statement

#000110465914034647 Filed on May 05, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold